



ASX Release
21 April 2026

Compumedics maintains strong demand with timing impacts to FY26; positions for improved FY27 execution

***MEG pipeline and connected platforms underpin medium-term growth
Record Revenue & Record EBITDA expected***

BUSINESS HIGHLIGHTS

- Record sales order momentum maintained, supporting medium-term revenue visibility across sleep and neuro platforms
- Revenue conversion impacted by timing factors, including
 - MEG installation scheduling delays associated with conflict-related disruption in the Middle East affecting helium availability and pricing, and
 - Deliberate prioritisation of manufacturing readiness for Somfit® D ahead of full commercial rollout
- SaaS and annuity platforms continue to expand, supporting improved revenue quality and recurring mix
- Cost discipline maintained, partially offsetting revenue timing delays and supporting earnings resilience
- Liquidity strengthened with material MEG cash receipts in Q3 FY26 and expanded working capital facilities providing \$10 million to \$11 million of available headroom
- FY26 guidance updated, with the Company still expecting strong year-on-year growth despite timing-related impacts:
 - Revenue: approximately \$62 million to \$65 million (up approx. 22% to 28% on FY25)
 - EBITDA: approximately \$5.5 million to \$7 million

PERFORMANCE OVERVIEW: FY26 YEAR TO DATE

Compumedics continues to deliver solid underlying operating performance, with strong order intake across core platforms. The current year-to-date result reflects timing differences between order intake and revenue recognition, particularly in capital equipment and MEG, rather than any deterioration in underlying demand.

1. Sales orders taken
 - Sales orders remain strong and supportive of growth outlook
 - Demand continues across:
 - Sleep diagnostics (capital and SaaS)
 - Neurology platforms
 - MEG pipeline opportunities
 - Order book provides clear visibility into future revenue conversion, particularly into FY27
2. Revenue reported (shipped and invoiced)
 - Revenue conversion has been slower than anticipated, reflecting:
 - MEG shipment and installation timing
 - Supply chain constraints, including helium availability and pricing pressures arising from ongoing conflict-related disruption in the Middle East
 - A later Somfit® D rollout in the US, reflecting a deliberate focus on manufacturing readiness and quality of deployment
 - These factors are timing-related, with revenue expected to progressively convert
3. Cost base and profitability
 - EBITDA performance remains resilient, supported by:
 - Active cost management across the group
 - US cost base reset implemented in January
 - The benefit of higher revenue scale, with year-on-year revenue growth of 22% to 28% supporting improved absorption of the group cost base
 - This improved scale has helped offset timing-related delays in other parts of the business and supported a stronger earnings outcome than would otherwise have been the case

INVESTOR OVERVIEW

Sleep and Neurology business (including Somfit and Nexus 360 SaaS)

The Sleep and Neurology business continues to show stable to improving performance across most regions, with ongoing growth in connected platforms:

- Continued expansion of SaaS and annuity revenue streams
- Increasing integration into pharmaceutical and CRO ecosystems
- Strengthening installed base supporting recurring revenue

United States

- Performance remains below expectations, primarily in capital equipment
- Management has implemented a targeted commercial reset, including:
 - Leadership changes
 - Cost base alignment
 - Increased focus on execution and conversion
 - Somfit and Nexus 360 continue to demonstrate underlying demand, with Somfit® D expected to support improved momentum following launch

Asia-Pacific and Europe

- Australia, North Asia and Europe continue to perform solidly
- China distributor activity and European tenders supporting ongoing momentum
- Regions provide important diversification and growth stability

Orion LifeSpan MEG business

MEG remains a high-value growth platform, with strong underlying demand:

- Existing MEG orders progressing toward installation
- Additional opportunities advancing through pipeline
- Revenue timing impacted by:
 - Installation scheduling
 - Helium availability and pricing pressures linked to disruption in the Middle East, affecting deployment timing

Importantly, these factors impact timing rather than demand, with revenue expected to carry into FY27

CORPORATE

Key growth initiatives

The Company continues to progress key initiatives to support near-term execution and FY27 growth:

- SaaS and connected platforms: scaling Somfit and Nexus 360 to increase recurring revenue mix
- MEG scale-up: converting strong order pipeline into installations and revenue
- Somfit® D rollout:
 - Initial deployments underway
 - US commercial launch now expected late June / early July
 - Rollout timing reflects a deliberate focus on manufacturing readiness and quality of deployment, positioning the product for sustainable scale
- US execution reset:
 - Leadership changes and cost realignment completed
 - Focus on improving conversion and accountability
- Cost discipline:
 - Continued focus on operating efficiency
 - Ongoing review of supplier and overhead cost base

Funding and financial flexibility

Compumedics maintains a strong liquidity position, supported by:

- Material MEG cash receipts in Q3 FY26
- Expanded banking facilities
- Total available liquidity of approximately \$10 million to \$11 million

This provides adequate funding flexibility to support operations and growth initiatives.

FINANCIAL OUTLOOK

Compumedics has updated its FY26 guidance to reflect timing-related impacts:

- Revenue: approximately \$62 million to \$65 million, representing approximately 22% to 28% growth on FY25
- EBITDA: approximately \$5.5 million to \$7 million

The revised outlook reflects:

- Deferral of MEG revenue into FY27, including impacts from helium-related supply constraints linked to ongoing disruption in the Middle East
- Later-than-expected Somfit® D contribution, reflecting a quality-first manufacturing and rollout approach
- Lower first half contribution from the US business

Even with these timing-related impacts, the updated revenue range reflects strong year-on-year growth, reinforcing confidence in the underlying trajectory of the business.

The Company continues to expect further strong growth through FY27, supported by:

- Conversion of the existing order book
- Commercialisation and scaling of Somfit® D
- Continued growth in SaaS and recurring revenue streams

OUTLOOK

While FY26 performance has been impacted by timing factors, Compumedics remains confident in:

- The strength of its underlying demand environment
- Its technology and product portfolio
- Its positioning for improved growth and earnings in FY27

Management remains focused on execution, revenue conversion and cost discipline through the balance of FY26.

About Compumedics Limited

Compumedics Limited [ASX: CMP] is a leading global medical device company that develops, manufactures, and commercialises diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring applications. The Company owns Neuroscan, based in the USA, and DWL Elektronische Systeme GmbH, based in Germany. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe, and the Middle East.

Executive Chairman Dr. David Burton founded Compumedics in 1987. The same year, the Company successfully designed and installed the first fully computerised Australian sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on developing products for the growing international sleep clinic and home monitoring markets.

Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia's Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian Governments.

For further information, please contact:

Dr. David Burton

Executive Chairman, CEO

P: +61 3 8420 7300

F: +61 3 8420 7399

David Lawson

Director, CFO

P: + 61 3 8420 7300

F: +61 3 8420 7399

Authorised for lodgement by Compumedics Limited's Board of Directors